Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections
Molecular Pharmaceutics · 04.09.2023 · 20 (9) · 4640-4653
DOI: 10.1021/acs.molpharmaceut.3c00395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 22.08.2023. Verfasst von Varsha V Nair und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, Texas 787…. Hauptthemen laut MEDLINE: Pneumonia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
Tigecycline (TIG) is a broad-spectrum antibiotic that has been approved for the treatment of a number of complicated infections, including community-acquired bacterial pneumonia. Currently it is available only as an intravenous injection that undergoes rapid chemical degradation and limits the use to in-patient scenarios. The use of TIG as an inhaled dry powder inhaler may offer a promising treatment option for patients with multidrug-resistant respiratory tract infections, such as Stenotrophomonas maltophilia (S. maltophilia). This study explores the feasibility of engineering an inhaled powder formulation of TIG that could administer relevant doses at a wide range of inhalation flow rates while maintaining stability of this labile drug. Using air-jet milling, micronized TIG had excellent aerosolization efficiency, with over 80% of the device emitted dose being within the respirable range. TIG was also readily dispersed using different inhaler devices even when tested at different pressure drops and flow rates. Additionally, micronized TIG was stable for 6 months at 25 °C/60% RH and 40 °C/75% RH. Micronized TIG maintained a low minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) of 0.8 μM and >0.5 μM, respectively in S. maltophilia cultures in vitro. These results strongly suggest that the micronization of TIG results in a stable and respirable formulation that can be delivered via the pulmonary route for the treatment of lung infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, Texas 78712, United States.
ORCID-Profile: Varsha V Nair
Zitieren
APA
Nair, V. V., & Smyth, H. D. C. (2023). Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections. Molecular Pharmaceutics, 20(9), 4640-4653. https://doi.org/10.1021/acs.molpharmaceut.3c00395
Vancouver
Nair VV, Smyth HDC. Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections. Molecular Pharmaceutics. 2023;20(9):4640-4653. doi:10.1021/acs.molpharmaceut.3c00395
BibTeX
@article{Nair2023,
author = {Nair, Varsha V and Smyth, Hugh D C},
title = {Inhalable Excipient-Free Dry Powder of Tigecycline for the Treatment of Pulmonary Infections},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {9},
pages = {4640--4653},
doi = {10.1021/acs.molpharmaceut.3c00395}
}
EUVIMED